Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

13 Oct 2003

Abstract excerpt

Despite the popularity of adeno-associated virus 2 (AAV2) as a vehicle for gene transfer, its efficacy for liver-directed gene therapy in hemophilia A or B has been suboptimal. Here we evaluated AAV serotypes 2, 5, 7, and 8 in gene therapy of factor VIII (FVIII) deficiency in a hemophilia A mouse model and found that AAV8 was superior to the other 3 serotypes. We expressed canine B domain-deleted FVIII cDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14551134
DOI: 10.1182/blood-2003-08-2954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotypePMID 14551134Read ↗

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.Semantic proximity Read ↗

Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in DogsSemantic proximity Read ↗

Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs.Semantic proximity Read ↗

Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.Semantic proximity Read ↗

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.Semantic proximity Read ↗

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia ASemantic proximity Read ↗

Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A MiceSemantic proximity Read ↗

Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene TherapySemantic proximity Read ↗

Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapySemantic proximity Read ↗

Gene therapy for hemophiliaSemantic proximity Read ↗

Gene Therapy for Hemophilia.Semantic proximity Read ↗

Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII DeficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.